Variant position: 379 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 693 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human PQPQLQGSHSHPSLPASSLA RHVLPTTSLGHPSLSAPALSS
Mouse PQPQLQGSHSHPSLPASSLA HHALPTTSLGHPSLSAPALSS
Rat PQPQLQGSHSHPSLPASSLA HHALPTTSLGHPSLSAPALSS
Bovine PQPQLQGSHSHPSLPASSLA RHALPTTSLGHPSLSAPALSS
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
2 – 693 CREB-regulated transcription coactivator 2
336 – 408 Ser-rich
368 – 368 Phosphoserine
393 – 393 Phosphoserine
368 – 368 S -> A. Reduced cAMP- and calcium-regulated phosphorylation.
393 – 393 S -> A. No effect on cAMP- and calcium-regulated phosphorylation.
Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells.
Iourgenko V.; Zhang W.; Mickanin C.; Daly I.; Jiang C.; Hexham J.M.; Orth A.P.; Miraglia L.; Meltzer J.; Garza D.; Chirn G.-W.; McWhinnie E.; Cohen D.; Skelton J.; Terry R.; Yu Y.; Bodian D.; Buxton F.P.; Zhu J.; Song C.; Labow M.A.;
Proc. Natl. Acad. Sci. U.S.A. 100:12147-12152(2003)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT CYS-379; FUNCTION;
Single nucleotide polymorphisms in genes encoding LKB1 (STK11), TORC2 (CRTC2) and AMPK alpha2-subunit (PRKAA2) and risk of type 2 diabetes.
Keshavarz P.; Inoue H.; Nakamura N.; Yoshikawa T.; Tanahashi T.; Itakura M.;
Mol. Genet. Metab. 93:200-209(2008)
Cited for: VARIANT CYS-379; INVOLVEMENT IN SUSCEPTIBILITY TO NIDDM;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.